Countries covered: France
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts.
Please Note: this is delivered as a Zip file.
Additional Information
At US$794, France has one of the highest pharmaceutical per capita consumption levels in the world. The pharmaceutical market is also one of the world’s largest, with total spending valued at US$49.6 billion in 2009.
Overall market growth has been comparatively low at around 5.0% per annum and is expected to average 3.0% in the medium term with government cost-containment programmes exerting downward pressure on reimbursable products. The hospital market has been much more dynamic with growth rates twice this figure in recent years, although steps are now being taken to introduce greater regulatory controls in this sector.
The underdeveloped generics market is undergoing rapid expansion boosted by government incentives and the loss of patent protection for several high-volume products. The stagnating OTC market is also finally set to expand as a result of government moves to end reimbursement for a wide range of products assigned a low medical value rating.
France is the third largest producer of pharmaceuticals in the world, accounting for 7% of global pharmaceutical output. Many multinationals have strategic manufacturing sites in France. However, the country is gradually losing out competitively to other European countries with more attractive business environments, such as Ireland, and to low cost producers in Eastern Europe and South America.
The increasingly competitive business environment has resulted in many smaller independent producers being acquired by multinational groups, the latest examples being the acquisition of Fournier Pharma by Solvay of Belgium and the acquisition of Negma-Lerads by Wockhardt of India.
France has also lost ground in the field of pharmaceutical research with the majority of multinationals preferring to concentrate their research efforts in their home country or in the US. Oncology research remains one of the few growth areas, due to the launch of a national cancer plan.
Related Reports:
Snapshots Hungary Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Poland Pharmaceuticals and Healthcare Report Q1 2010
Nigeria Pharmaceuticals and Healthcare Report Q1 2010
Australia Pharmaceuticals and Healthcare Report Q1 2010
Thailand Pharmaceuticals and Healthcare Report Q1 2010
Kenya Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
